Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 6 , Pages 1167-1173 , June 2009

Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the Jaws

  • Ranjit Kunchur, BDS, MDS

      Affiliations

    • Registrar, Oral and Maxillofacial Surgery Unit, University of Adelaide School of Dentistry, Adelaide, South Australia, Australia
    • ,
  • Allan Need, MD, FRACP

      Affiliations

    • Chemical Pathologist, South Australian Pathology, and Associate Professor, University of Adelaide Medical School, Adelaide, South Australia, Australia
    • ,
  • Toby Hughes, PhD

      Affiliations

    • Lecturer in Statistics, University of Adelaide School of Dentistry, Adelaide, South Australia, Australia
    • ,
  • Alastair Goss, DDSc, FRACDS (OMS), FICD

      Affiliations

    • Professor and Director, Oral and Maxillofacial Surgery Unit, University of Adelaide School of Dentistry, Adelaide, South Australia, Australia
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Goss: Oral and Maxillofacial Surgery Unit, University of Adelaide School of Dentistry, SA 5005 Australia

References 

  1. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  3. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253
  4. Carter G, Goss AN. Letters to the editor: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003;48:268
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  6. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567
  7. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J. 2005;50:S4;(Medications in Dentistry suppl 2)
  8. Expert Panel Recommendations. Dental management of patients receiving oral bisphosphonate therapy. J Am Dent Assoc. 2006;137:1144
  9. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  10. Sambrook P, Olver I, Goss AN. Bisphosphonates and osteonecrosis of the jaw: Position statement on behalf of the Australian and New Zealand Bone Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Society. Aust Fam Physician. 2006;35:801
  11. Mavrokokki A, Cheng A, Stein B, et al. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415
  12. Need A: Controlling osteoporosis. INVS Newsletter 61, 2006
  13. Need A: Serum β CrossLaps—A bone resorption marker. IMVS Newsletter 64, 2007
  14. Rosen HN, Moses AC, Garber J. Serum CTX: A new marker of bone resorption that shows treatment effects more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcific Tissue Int. 2000;66:100
  15. Marx RE. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention and Treatment. Hanover Park, IL: Quintessence Publishing; 2007;
  16. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg. 2007;65:2397
  17. Oral and Dental Expert Group. Therapeutic Guidelines Oral and Dental Therapeutic Guidelines (Melbourne) with the Australian Dental Association, Version 1. West Melbourne, VC, Australia: Therapeutic Guidelines Limited; 2007;pp 75-79
  18. Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J. 2008;53:354
  19. Malmgren B, Aström E, Söderhäll S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;66.6:1320
  20. Khosla S, Burr D, Cawley J, et al. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using CTX testing, prevention and treatment (Letter to the editor). J Oral Maxillofac Surg. 2008;66:1320
  21. Marx R: In reply to Khosla S, Burr D, Cawley J, et al: Letter to the editor. J Oral Maxillofac Surg 66:1321, 2008
  22. Dayton L: Doctors angered by ABC report on bone drugs. The Australian December 19, 2007
  23. Sambrook P. Bisphosphonate update (Australian Dental Association, Dental Files. Program 3). St. Leonards, NSW, Autralia: Australian Dental Association; 2008;
  24. Schifter M, Cox S, Clayden A. The CTX test and bisphosphonate-associated ONJ. ADA News Bulletin. 2008;371:21
  25. National Prescribing Service (Australian). Maintaining bone health to prevent osteoporotic fractures. NPS Bulletin 53, August 2007

PII: S0278-2391(09)00175-X

doi: 10.1016/j.joms.2009.02.004

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 6 , Pages 1167-1173 , June 2009

Article Tools